Hemodialysis for chronic renal failure was introduced and developed in Seattle, WA, in the 1960s. Using Kiil dialyzers, weekly dialysis time and frequency were established to be about 30 hours on 3 time weekly dialysis. This dialysis time and frequency was associated with 10% yearly mortality in the United States in 1970s. Later in 1970s, newer and more efficient dialyzers were developed and it was felt that dialysis time could be shortened. An additional incentive to shorten dialysis was felt to be lower cost and higher convenience. Additional support for shortening dialysis time was provided by a randomized prospective trial performed by National Cooperative Dialysis Study (NCDS). This study committed a Type II statistical error rejecting the time of dialysis as an important factor in determining the quality of dialysis. This study also provided the basis for the establishment of the Kt/V urea index as a measure of dialysis adequacy. This index having been established in a sacrosanct randomized controlled trial (RCT), was readily accepted by the HD community, and led to shorter dialysis, and higher mortality in the United States. Kt/V urea is a poor measure of dialysis quality because it combines three unrelated variables into a single formula. These variables influence the clinical status of the patient independent of each other. It is impossible to compensate short dialysis duration (t) with the increased clearance of urea (K), because the tolerance of ultrafiltration depends on the plasma-refilling rate, which has nothing in common with urea clearance. Later, another RCT (the HEMO study) committed a Type III statistical error by asking the wrong research question, thus not yielding any valuable results. Fortunately, it did not lead to deterioration of dialysis outcomes in the United States. The third RCT in this field ("in-center hemodialysis 6 times per week versus 3 times per week") did not bring forth any valuable results, but at least confirmed what was already known. The fourth such trial ("The effects of frequent nocturnal home hemodialysis") too did not show any positive results primarily due to significant subject recruitment issues leading to inappropriate selection of patients. Comparison of the value of peritoneal dialysis and HD in RCTs could not be completed because of recruitment problems. Randomized controlled trials have therefore failed to yield any meaningful information in the area of dose and or frequency of hemodialysis.
INTRODUCTION
Home hemodialysis was introduced in Seattle in 1964 and developed gradually over the years. It is currently widely practiced in New Zealand and Australia. In the United States, its prevalence is below 2% of hemodialysis population. Most of the progress in dialysis methods has been possible due to research presented in case reports, case controlled studies, before-and-after design studies, and other observational studies. Clinical assessment of the patient remains the best criterion of dialysis quality. Longer dialysis provides better tolerance of ultrafiltration, less frequent intradialytic hypotensive episodes, better control of blood pressure, and lower mortality. This is due to better control of volume overload, which is dependent on proper removal of sodium, the most important uremic toxin. There is a tendency to establish mortality as the most important measure of the hemodialysis value. However, "there is more to life than absence of death." Not only should we pay attention to patient reported outcomes, regular objective assessment of parameters like blood pressure, frequency, and intensity of hypotensive episodes, levels of phosphorus, albumin, hemoglobin, beta2-microglobulin, and so forth, is mandatory as well. Such monitoring should lead to adjustments of individual patient prescriptions and observing outcomes (before and after design in a single patient). More frequent (than 3 times weekly) hemodialysis schedule without the "Two Day Killer Gap" provides much better results. Such treatments can be provided in the clinic or at home (depending on reimbursement). Residual renal function, (determined not by glomerular filtration rate but by daily urine output) is an important factor in assessing the time and frequency of hemodialysis. Also, the ability to be gainfully used, especially for younger patients should be one of the most important measures of dialysis quality. It seems that most patients with urine output less than 500 mL/d may require 15-17 hours of weekly dialysis time [with dialyzer blood flow of 250 mL/min (or lower) and frequency of dialysis that is higher than 3 times a week. We believe that with this schedule, mortality in the United States can be significantly lowered. Patients dialyzed over 7-8 hours per session may not require more than 3 times weekly sessions.
HISTORICAL BACKGROUND OF CHRONIC HEMODIALYSIS DURATION AND FREQUENCY

In the beginning
There was no successful modality for treating chronic renal failure until March 1960, when a new chapter in the therapy of chronic renal failure was opened, mostly because of tremendous contributions of Belding Hibbard Scribner.
1 Wayne Quinton, an engineer working in the Washington University Hospital medical instrument shop, had developed dialysis cannulas and shunts using Teflon tubing, which remained patent for days. 2 On March 9, 1960, Dr. David Dillard, a pediatric heart surgeon, implanted the first Teflon shunt into the forearm of Clyde Shields, a Boeing machinist, who had been admitted to Scribner's service with severe uremia from chronic renal failure. His BUN was 120 mg/dL, serum creatinine was 20 mg/dL, with a clouded sensorium and evidence of uremic twitching. Using the technique of continuous dialysis, as developed for the treatment of acute renal failure, Clyde was dialyzed for 76 hours. The results were spectacular. He became ambulatory for the first time in weeks, stopped vomiting, and felt generally well for several days. With a second hemodialysis treatment, begun on March 21, 1960 , he became the first chronic intermittent hemodialysis patient in Seattle. On March 23, a second patient, Harvey Gentry, also started intermittent hemodialysis. A report on the treatment of these two patients was published in 1960. 3 Dr. George Schreiner, the then Editor of "Transactions," decided to publish this report despite the fact that these findings were not presented during the meeting (underscoring the clinical importance of these findings). 4 Two more patients were started on hemodialysis in the next 3 months. Initially, dialysis sessions were performed every 7 to 14 days for 24 to 48 hours, but soon the frequency of dialysis was increased; so that dialysis were performed for 24 hours every 5-7 days using Skeggs/Leonards dialyzers. Experience with these first four patients was presented at the 1961 meeting of the American Society for Artificial Internal Organs (ASAIO). 5 All four patients survived in spite of multiple problems, including hypertension, vomiting, lethargy, and hyperkalemia before dialysis, hypotension after dialysis, neuropathy, gouty attacks, and severe anemia. Continuous diligent observation of the patients and improvements in the equipment and technique led to continued improvement in the patients' conditions. Each consecutive presentation and publication revealed important improvements in therapy. Teflon, which, because of its nonstick properties, prevented clotting, but proved to be so stiff that the rigid cannula tip damaged the intima of the blood vessels every time the patient moved his arm. Quinton solved this problem by replacing part of the cannula with flexible, smooth, hydrophobic, silicone rubber tubing to act as a shock absorber. 6 In 1961, Scribner brought home a four-layer Kiil dialyzer from Copenhagen. This device, originally designed as a blood oxygenator, was a flat plate dialyzer similar to the Skeggs/Leonards dialyzer, but very well manufactured, easier to assemble, and more reliable. It proved so successful that Scribner convinced Martin Headman, Director of Research at the Western Gear Corporation in Los Angeles, to manufacture Kiil boards. This company, which had no real interest in medical devices, supplied Kiil boards for many years.
Four more patients were started on hemodialysis in Seattle in 1961, and the results were presented during the Eighth Annual Meeting of the ASAIO, held in 1962. 8 The patients had received the new silicone-Teflon cannulas, Skeggs/Leonards dialyzers had been replaced by Kiil dialyzers, and dialysis frequency had been increased to twice weekly in those patients that had lost residual renal function. Neuropathy improved with more frequent dialysis, and the role of the calcium phosphate product in metastatic calcifications and pseudo-gouty attacks was recognized. Only one patient died during the first 2 years of the Seattle chronic dialysis program.
The basis for success was careful observation, attention to details, and complete devotion to both the patients and the program. This observation highlighted the need to increase the frequency of dialysis in patients losing residual renal function. Initially, others had difficulty emulating the results achieved by Scribner and his group mostly because the frequency of dialysis was different than that of Seattle. Brandon et al. published their experience of dialysis treatment in 1962. Six patients in terminal chronic renal failure had been maintained on a program of prolonged (approximately 20 hours), periodic hemodialysis using the twin coil artificial kidney. Dialysis was conducted at six or seven day intervals. Major complications encountered during 65 long dialysis were reported as dehydration from excessive ultrafiltration, hypertension, convulsions, and bleeding episodes. Complications encountered during the intervals between dialysis were dehydration, pulmonary congestion, hypertension, anemia and, rarely hyperkalemia. 9 This experience indicated that once weekly 20 hours dialysis was insufficient.
For the next several years, most of the improvements in chronic dialysis therapy were made at Seattle, which became the Mecca for all who wanted to study dialysis. Many departments at the University of Washington collaborated with the Division of Nephrology, and the atmosphere of cooperation, progress, and inventiveness was so prevalent that even patients participated in the research. During the Eighth Annual Meeting of the ASAIO, Dr. James R. Albers, a physicist and the fifth chronic hemodialysis patient, presented a paper on the frequency of changing the dialysis bath to obtain optimal results. 10 The audience did not realize that the presenter was himself a patient, and most of them could not comprehend the complex mathematical approach he suggested. 11 Dr. Albert L. Babb, Professor of Nuclear Engineering at the University of Washington, 12 developed the first proportioning system that prepared dialysate from purified water and concentrate, which could be used to supply a number of hemodialyzers simultaneously. This prototype, much larger than necessary because the components were "borrowed" from various student projects, was dubbed "The Monster" by Clyde Shields. 7 Because bicarbonate precipitates if calcium and magnesium are present in the same concentrate, the original design used three pumps, one for sodium bicarbonate, one for other salts, and the third for water. 13 However, Charles Mion, a visiting fellow from Montpellier, France, found that acetate could be substituted for bicarbonate and so the equipment was redesigned to use only two pumps. 14 An additional advantage of acetate concentrate over bicarbonate was that acetate concentrate is self-sterilizing, whereas bicarbonate concentrate is not. Although acetate later turned out to be inappropriate for use with very high-efficiency dialyzers, it served well for almost two decades and facilitated the development of many dialysis units.
The next major advance in Seattle was the advent of home hemodialysis. In 1964, a 16-year-old high school student Caroline Helm was dying of terminal uremia, and at that time the strict acceptance criteria of the Seattle Artificial Kidney Center excluded patients under the age of 18. She and her parents were highly motivated to do everything possible to save her life. Fortuitously, her father knew Dr. Babb. The Monster had just been completed, so Babb and his colleagues undertook a crash program to develop a smaller one-person version of the Monster, the Mini-Monster or "Mini" for home use. 7 On April 5, 1964, this patient was started on hemodialysis, and she and her parents were trained to operate the artificial kidney machine in a room in the University Hospital. Within a few months, the patient was being dialyzed at home, without medical supervision. 15 Because assembly of the Kiil dialyzer was a real burden to patients and their families, the Seattle group developed a technique for storage and reuse of dialyzers. With this technique, patients would rebuild their dialyzers only once every 2 weeks instead of for each treatment. 16 The Seattle home dialysis program proved to be very successful, and for several years the University of Washington operated a Remote Home Dialysis Program serving patients from the Northwest and elsewhere in the United States and from abroad. 17 By the end of 1960s, the definition of adequate dialysis was based on the two essential goals of dialysis: eradication of signs and symptoms of uremia and rehabilitation. Based on these goals the frequency and time of dialysis on standard Kiil dialyzers in-center was determined to be 20-40 h/wk depending on residual renal function. No blood pressure medications were needed in 22 of 24 (92%) of patients. 18 By the same criteria, it was determined that home hemodialysis should be performed on Kiil dialyzer 8-10 hours thrice weekly. 19 No blood pressure medications were needed in 29 of 33 (88%)
The need to shift the focus to sodium removal in dialysis patients Hemodialysis International 2018; 22:S29-S64 S31 patients. Hypotensive episodes were so rare that they were not even mentioned as complications of hemodialysis in these two classic papers. 18, 19 Very meticulous emulations of Seattle hemodialysis method performed in Royal Free Hospital in London determined that no blood pressure medications were needed in 89 patients with 10 hours of hemodialysis thrice weekly. The authors recommended very meticulous initiation of therapy to achieve dry weight. 20 By the late 1960s, most of the basic technical problems had been solved. The results with arteriovenous shunts were good, and some patients kept the same shunt for many years. Blood access was markedly simplified with development of the arteriovenous fistula in 1966. 21 Home hemodialysis was expanding; patients living far from Seattle were being trained and followed with the cooperation of local physicians. 17 The most important question became the amount of dialysis necessary to eradicate the symptoms of uremia and to give the greatest opportunity for rehabilitation. Scribner, an astute clinician, made several extremely important observations. First, he observed that patients with residual renal function were not likely to develop uremic symptoms, including peripheral neuropathy, which was common in anuric patients. Second, it became clear that twice-weekly dialysis were not sufficient to arrest the progression of peripheral neuropathy in patients without residual renal function, and so three times weekly dialysis became routine in the later 1960s. 6, 11 Third, Dr. Scribner noted that early patients on chronic peritoneal dialysis did not develop neuropathy, despite poor small molecule clearance. This observation led to the conclusion that the peritoneum was clearing some neurotoxins more efficiently than the small-pore membranes of the early hemodialyzers. 22 However, another factor that was not taken into account was that weekly peritoneal dialysis duration was markedly longer than hemodialysis and there were no fluctuations of the concentrations of toxic substances and fluid volumes.
STUDIES OF OUR OF HD ADEQUACY FROM MARCH 1969 TO MAY 1973
The results of this study were published in three parts in 1974 and 1975. [23] [24] [25] A total of 14 patients, aged 19-56 years, (with chronic renal failure caused by isolated renal diseases) were treated with hemodialysis. The frequency and duration of dialysis were adjusted to obtain adequate hemodialysis. On the basis of the clinical state of the patients four grades of adequacy of hemodialysis were determined. Adequate hemodialysis was defined as a method of treatment that could relieve the patient of all clinical manifestations of uremia as well as provide complete rehabilitation.
It was decided that the following clinical manifestations of uremia would be taken into account in the classification of adequacy: nausea, vomiting, loss of appetite, bad taste in mouth, gastric pain, restless legs syndrome, burning feet syndrome, motor neuropathy, bone pains, pathological fractures of bones, metastatic calcifications, pseudogout attacks, diastolic arterial pressure above 95 mmHg before dialysis and 90 mmHg after dialysis, circulatory failure, arrhythmia due to hyperkalemia, pericarditis, exudative pleuritis, amenorrhoea in women below the age of 40 years, impotence in males, hemorrhagic diathesis, insomnia, dizziness, and headaches during dialysis. Also a degree of rehabilitation was taken into account when assessing dialysis adequacy. A full rehabilitation was accepted if patients were able to work without sickness absences due to uremia. The following symptoms and signs were considered as complications of dialysis: insomnia only at the time of dialysis, muscle cramps, hypotension, and weakness after dialysis.
Hemodialysis was performed on the RSP Travenol artificial kidney and Ultra Flo145 coil dialyzers. The blood flow was kept at 200 mL/min and the dialysate flow at 500 mL/min. A single dialyzer was reused several times during 3 weeks in a given case. 26 No blood transfusions and anabolic steroids were given. Erythropoietinstimulating agents were not available at that time. Using this method it was possible to achieve adequate hemodialysis with two procedures of 12 hours each twice weekly in three patients with a 24-hour urine output of greater than 500 mL. These patients preserved urine output over 500 mL/d extremely well for many years. In the remaining cases with a lower urinary output, adequate hemodialysis could be achieved with three sessions of 8 or 9 hours per week. In some patients with uremic manifestations refractory to treatment, four sessions of 6 or 7 hours each were required weekly. As the postdialysis body weight of study patients ranged between 47 and 76 kg, it was not possible to predict the number of procedures per week necessary for a patient. 23 There was excellent correlation between the hemodialysis adequacy and following measurements: serum albumin concentrations, blood pressure before-and-after dialysis, serum albumin concentration, hematocrit, nerve conduction values, and residual kidney function. More importantly, the correlation with urine output in the range of 100-750 mL/day was better than with creatinine clearance in the range of 0.5-5.5 mL/min. 22 This indicates that it is more important to measure urine output than creatinine clearance below 15 mL/min to predict the appropriate dialysis dose in a patient. There was no correlation between the clinical condition of the patient and the following variables: predialysis serum urea [(86-172 mg/100 mL) and postdialysis serum urea (18-64 mg/100 mL), and predialysis serum creatinine (6.7-14.3 mg/100 mL) and postdialysis serum creatinine (2.3-6.8 mg/100 mL). 24 Another publication 25 presented the correlation of various parameters with dialysis frequency or duration. The correlation between various parameters and dialysis frequency and duration was calculated with Student's t test for paired samples. The "Student" (real name: Willliam Sealy Gossett ) developed statistical methods to solve problems stemming from his employment in a brewery. In 1908, he published two articles, which established t test statistics for small samples. 27, 28 Student's t test deals with the problems associated with inference based on "small" samples: the calculated mean and standard deviation may by chance deviate from the "real" mean and standard deviation (i.e., what you would measure if you had many more data items: a "large" sample). This kind of statistics is useful for comparison of two methods applied consecutively (before and after design; A-B or A-B-A) in the same, small, group of patients. The paired t statistics, also introduced by "Student" (dealing with the problems associated with inference based on "small" samples) is also very reliable since it reduces intersubject variability by comparing observations between the same subjects. This method cannot compare mortality.
Serum albumin concentration was calculated from determinations of the whole protein by the burette method 29 and proteinogram was obtained by paper electrophoresis and read with a Zeiss densitometer. 30 This method gives lower values than by methods that are currently used. Series of figures was included in our third paper in these series showing the correlations between frequency or time of dialysis and serum albumin or nerve conduction velocity (Figure 1 ), systolic and diastolic blood pressures (Figure 2 ), dry body weights and weight differences between dialysis (Figure 3 ), hematocrit (Figure 4 ), urea and creatinine ( Figure 5 ). The blood samples for determining urea and creatinine and hematocrit were obtained before-and-after dialysis, whenever required. The total blood loss caused by sample taking, insertion of needle into the internal fistula, and blood remaining in the dialyzer was about 20 mL per dialysis. The additional blood loss caused by sample taking for routine determinations was about 90 mL monthly. After increasing the frequency or duration of dialysis no more transfusions of donor blood were given to the patients. No androgens were administered.
The conclusions in this publication were as follows: (1) Frequent and short-lasting dialysis is much more effective in treatment of uremic manifestations than longer but less frequent dialysis. (2) Increased frequency of dialysis has a very favorable effect on hamatocrit value, albumin concentration, motor nerve conduction velocity and dry body weight. (3) Prolongation of dialysis duration without changing the frequency improves the value of hematocrit and albumin concentration, although this improvement is less pronounced than after increased frequency of dialysis. (4) Increase in the frequency as well as duration of dialysis causes a drop of arterial blood pressure, particularly in hypertensive patients. Increasing the frequency of dialysis by once a week, or duration of dialysis by 17.5%, had no significant effect on the concentration of preurea or posturea and creatinine when these parameters were determined after a mean period of 6.4 months after increasing the frequency of dialysis or after a mean time of 6.9 months after increasing the duration of dialysis. At the same time, the patients gained dry body weight, so the increased removal of urea and creatinine were compensated by increased protein intake and creatinine production with higher muscle mass. Cramps, hypotensive episodes during dialysis and prolonged recovery time after dialysis were very rare. Almost all patients accepted longer and/or more frequent dialysis as they felt better and could change diet. With longer and more frequent dialysis the patients could change diet to containing more salt. One of our patients in whom the necessity of dietary restrictions was particularly stressed in view of arterial hypertension explained that the recommended low-salt diet caused loss of appetite, abdominal pains, weakness, and irritability. The patient accepted an increase in the frequency of dialysis and reduction of dietary restrictions for relief from troublesome symptoms. Lately, the diet has been made much less strict. The mean protein intake calculated on the basis of a weekly diary given to patients ranged from 0.90 to 1.25 g/kg per 24 hours. The intake of sodium exceeded 100 mEq per 24 hours in many patients, judging from the weight gains in the intervals between dialysis. One patient had headaches during dialysis. The headaches were, undoubtedly, a consequence of disequilibrium syndrome of small intensity since they disappeared after a short trial of increasing the frequency of dialysis. However, this patient considered the intensity of this symptom so insignificant that he ruled out switching to more frequent hemodialysis. As a result of these studies we came to the conclusion that adequate dialysis with blood flow of 200 mL/min on coil dialyzers (in patients with 24-hour urine output greater than exceeding 500 mL), may be achieved with two procedures of 12 hours each twice weekly. However, patients with less 
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ATTEMPTS TO SHORTEN DIALYSIS DURATION
In 1965 a publication on shorter dialysis by Cambi et al. 31 indicated that shorter dialysis sessions (total duration of 12-16 h/wk with the use of coil dialyzers) achieve biochemical control similar to that reported by the "Seattle group." However, the blood pressure control was much worse in the Cambi group than what was reported by the Seattle group. In a group of 22 patients, 8 required antihypertensive therapies, 4 required bilateral nephrectomy, and 2 died of cerebral hemorrhage.
In the early 1970s, the number of candidates for chronic dialysis markedly exceeded the availability of treatment facilities. Vicenzo Cambi, a nephrologist in Parma, Italy, decided to maximize utilization of his dialysis unit by drastically shortening dialysis sessions. Whereas, in 1971, the Cambi patients were dialyzed on Kii1 dialyzers for 27 hours, in 1972 the patients were gradually switched to coil dialyzers and dialyzed 3 hours every other day for an average of 11.2 h/wk. 32 These authors reported that shorter dialysis was well-tolerated and hematocrits improved; they did not mention any problems with blood pressure control or hypotensive episodes. Residual renal function was not reported either. There "were only a few disadvantages," including higher phosphate levels and a "need of a 'routinely' high blood flow" of 250 mL/min. In a subsequent paper from Parma, the authors confirmed good results with short dialysis; however, they mentioned problems with blood pressure control to such a degree that two patients had to have bilateral nephrectomies. 33 Funk-Brentano et al. 34 reported improvement in nerve conduction velocities on 3-hours thrice weekly dialysis, using polyacrylonitrile membranes and plate dia1yzers.
In the late 1970s, an increasing number of centers in Europe and in the United States began following these recommendations. Short dialysis had tremendous appeal to the patients once they were told that the results were not worse than those with long dialysis.
What were the reasons for the widespread acceptance of short dialysis? Barth 35 argued that at least three factors were necessary to make it possible: technical feasibility, economic incentives, and medical/scientific justification. Economic incentives were demonstrated by the Parma group. Technical feasibility also appeared possible. A patent followed by a publication on the possibility of constructing a more efficient and smaller dialyzer (capillary dialyzer) with 250 mL volume and 6280 cm 2 dialyzing surface area 36, 37 soon appeared. Shortly thereafter, more efficient dialyzers were designed and manufactured. A hollow-fiber dialyzer with 9000 cm 2 dialyzing surface area and 130 mL internal volume was clinically tested and became commercially available in 1968. 38 Additionally, more efficient coil and parallel plate dialyzers were developed in the early 1970s, so removal of uremic toxins seemed to be possible in short-duration dialysis. Ari et al. 39 compared 7-hours twice weekly dialysis or 6-hours thrice weekly dialysis on a UF 145 with 3.5-hours twice a week or 3-hours thrice a week with two UF two coils in series (2 m 2 ), respectively. They found no differences between the pairs. Regardless, short-term studies could not be enough reasons for the widespread use of short dialysis. Additional scientific support and a mathematical basis were needed to define an adequate dose of dialysis and justify short treatment durations.
Because peripheral neuropathy was the uremic symptom most difficult to eradicate, adequacy of dialysis was defined as the amount that was necessary to prevent this complication. Peripheral neuropathy became rare when patients were dialyzed thrice per week for 24 to 27 hours weekly on standard Kiil dialyzers. Based on these observations, Scribner and Babb (Seattle Group) conceived the idea that the responsible toxins were bigger than small molecules such as urea and creatinine, but smaller than protein molecules, so they called them "middle molecules" (MM). Removal of this MM appeared to depend on membrane porosity, membrane surface area, and duration of dialysis. This hypothesis led to the "square meter-hour hypothesis," which implied that, by doubling the surface area of a hemodialyzer, the time of dialysis could be halved for an equivalent MM removal. 40 In the course of studies by the "Seattle group" 7 to prove the validity of the MM hypothesis, patients were dialyzed on three regular Cordis-Dow 1 m 2 hollow-fiber hemodialyzers, connected in series to create a 3 m 2 unit. This was an important step in the justification of high-efficiency, short-time dialysis. Thereafter, Cordis-Dow designed and marketed a 2.5 m 2 dialyzer. 7 Ultimately, the Seattle group developed the first quantitative description of adequacy of dialysis, the "dialysis index," which was calculated by the following formula:
where D I = dialysis index; T D = weekly dialysis time (hours); K B = MM clearance (depending mostly on membrane characteristics and ultrafiltration); K K = residual renal creatinine clearance; and S = body surface area.
This index took into account residual renal creatinine clearance, body surface area, weekly dialysis time, and dialyzer MM clearance. Please note that the formula takes into consideration residual renal function, which was omitted in formulas developed later.
This concept was presented at the Conference on Adequacy of Dialysis, Monterey, CA, March 20- 22, 1974 . 41 At the same conference, Scribner presented a comprehensive approach to the adequacy of dialysis that included both patient and dialysis system variables. 42 Patient variables included lean body mass, basal metabolic rate, activity level, residual renal function, diet, lifestyle, access problems, and intercurrent illness. Dialyzer-system variables included surface area, membrane characteristics, dialysis time, ultrafiltration requirements, dialysis frequency, and blood flow. Although a simple diagram was published to facilitate its use, 43 the dialysis index never gained popularity. More reports of short dialysis with higher dialyzer membrane surface area appeared in the late 1970s and early 1980s. Shaldon et al. 44 compared the results in groups of patients dialyzed either thrice weekly on a double reused Gambro Lundia (2 m 2 ) dialyzer for four and-a-half hours per dialysis or thrice weekly 5 hours per dialysis on a single use Gambro Lundia (1 m   2 ). There were no significant differences in nitrogen retention between the groups, nor did the mean motor nerve conduction velocity alter significantly in any patient. The authors noted that patients on longer dialysis experienced significantly fewer hypovolemic symptoms during dialysis, and they concluded that longer dialysis is preferred. Manji et al. 45 performed 6-7 hours thrice weekly dialysis using 1.3 m 2 hollow fiber kidneys (HFK) for 1 year in 11 patients and then switched them to The need to shift the focus to sodium removal in dialysis patients Hemodialysis International 2018; 22:S29-S64 S37 4-4.5 hours thrice weekly dialysis with 2-2.5 m 2 HFK for 1 year. The biochemical control was essentially the same, and hematocrit improved with shorter dialysis.
ATTEMPTS AT ULTRA-SHORT DIALYSIS
The results of the studies on shorter dialysis spurred other studies to demonstrate that dialysis time can be shortened to 6 hours or less per week by increasing blood flow and dialyzer surface area. Von Albertini et al. 46 evaluated 115 minutes sessions thrice weekly combining hemofiltration with dialysis (hemodiafiltration), utilizing two highsurface area (1.8 m 2 ) dialyzers in series and blood flows of 500 mL/min. They reported excellent biochemical control compared to 4-hour dialysis on smaller-surface-area dialyzers. It is of note that the frequency of hypotensive episodes was 0.4 per dialysis, and they used saline infusion to combat hypotension. Rotellar et al. 47 led off their paper with the statement, "Shortening the time of dialysis has always been an aim of physicians." Clearances of small molecules, nerve conduction velocities, and visually evoked potentials did not significantly differ when the time of dialysis was shortened from 12 h/wk to 6 h/wk, but dialyzer surface area and blood flow were doubled from 2.5 m 2 to 5 m 2 and 250 mL/min to 500 mL/min, respectively. In the discussion, which followed the presentation, Dr. Rotellar admitted that the dialysis were better tolerated in patients with residual urine output. 48 It is worth mentioning that early studies indicating benefits of short dialysis were carried out in patients starting chronic hemodialysis and thus in those with substantial residual urine output. The desire to use short dialysis sessions was very strong. One paper posed the question in the title "Are there limitations to shortening dialysis treatment?" and did not answer affirmatively. 49 
HOW KT/V UREA BECAME A YARDSTICK OF HD ADEQUACY
In the late 1970s and early 1980s, short dialysis received support from a new measure of dialysis adequacy based on urea kinetics. Gotch and Sargent recommended that the minimum dose of dialysis (dialyzer urea clearance, treatment time, and frequency) should be sufficient to result in mean predialysis blood urea nitrogen (BUN) values of 80 mg/dL in patients with documented protein intakes of at least 1.0 g/kg/d. 50 It is worth noting that, unlike the MM clearance, the urea clearance is significantly influenced by blood and dialysate flow rates because urea molecules diffuse rapidly through the membrane. Therefore, to maintain a high concentration gradient of urea between blood and dialysate, high blood and dialysis solution flow rates are required. The National Institutes of Health (NIH) sponsored the National Cooperative Dialysis Study (NCDS) to establish the objective, quantitative criteria for the adequate dose of dialysis. 51 Urea kinetics coupled with the monitoring of nutrition was chosen as the criterion of dialysis dose. 52 This was a randomized controlled trial (RCT) which compared outcomes in patients assigned to high or low urea levels and short (199 or 194 minutes) or long dialysis (269 or 271 minutes) times. It was accepted that the single measure of dialysis dose should be Kt/V urea : the amount of urea clearance (K) multiplied by time (t) and divided by urea distribution volume (V). Morbidity was used to judge the quality of dialysis. Patients with high BUNs and short hemodialysis durations were hospitalized more often compared to the group with high BUN but longer dialysis; however, this was statistically insignificant (P = 0.056) so in the final recommendations, the length of dialysis was considered as only marginally important. 53, 54 In later analysis of the National Cooperative Dialysis Study, Gotch and Sargent 55 concluded that "…a fully adequate dialysis prescription is provided with Kt/V = 1.0 … with thrice weekly treatment schedule." Figure 6 shows the derivation of Kt/V. C/C 0 is called urea reduction ratio (URR). Thus to calculate Kt/V you do not need to know time (t) or clearance (K) or urea distribution volume (V). You need to know predialysis and postdialysis urea concentration.
Why Kt/Vurea was enthusiastically accepted as a single measure of dialysis adequacy? It justified short dialysis, very convenient for organizational and financial reasons. The formula could be calculated from preconcentrations and postconcentrations of urea (C/C 0 ) without even knowing K or t or V. (K) or (t) or (V) It was not necessary to know any other data; blood to a laboratory and the results from the laboratory.
THE MAJOR SHORTCOMINGS OF NCDS
1. Residual renal function was not taken into account in spite that many patients were of short vintage and must have had substantial urine output. 2. Significant influence of time on hospitalizations between groups II and IV (high BUN) were ignored, instead calculated for combined groups I + II vs. III + IV. 3. Time of dialysis was rejected as a measure of dialysis adequacy based on P = 0.056 instead of 0.05 which indicates probability of 1 to 17 instead of 1 to 20 that it was by chance.
The forgotten truth: Absence of evidence is not evidence of absence, that is, typical statistical f3 error.
Is urea toxic?
If the quality of dialysis is dependent on Kt/V urea then it is needed to determine whether urea is really toxic. At the end of 18th century, it was discovered that the main constituent of urine is "urèe," "...the overload of … urea is capable of causing diseases." 56 In the next 50 years, there was no agreement about toxicity of urea. In France, it was determined that infusion of urea into blood of animals caused diuresis but not toxicity. 57 In England, it was claimed that uremic state is caused by retention of substances normally excreted by kidneys, particularly urea. 58 In the second half of 19th century, urea was not considered as toxic because its level did not rise much in anephric animals 59 and injection of urea to anephric animals did not influence mortality. 60 In 1881, it was determined that the most toxic constituent of urine is potassium. 61 Early in the 20th century all authors of early dialysis ) (peritoneal and Extracorporeal) assumed that urea toxicity and urea concentrations served as measures of dialysis efficiency and that high urea level was an appetite suppressant. Others argued that sharks have voracious appetite and BUN level over 1000 mg/dL. At some point, Willem Johan Kolff showed a container with 270 g of urea, which was the amount removed during hemodialysis in one patient with acute renal failure. He said that those who cannot believe in urea toxicity should swallow this amount and see how they would feel.
In the second half of the 20th century very careful studies were done during dialysis with addition of urea into dialysate. Teschan et al. 62 determined that mental performance in well trained monkeys deteriorated after ureteral ligation when BUN level rose to 50-200 mg/dL, but restored to normal after peritoneal dialysis with urea added to dialysate. EEG changed accordingly. The story of Teschan achievements were presented in a laudation in 1998. 63 Studies in patients in Mayo Clinic 64 showed that urea is toxic only at very high levels. BUN of 181-600 mg/dL, maintained by adding urea to hemodialysate, was well-tolerated. Higher values were associated with malaise, vomiting, and headaches.
The major problem with Kt/V urea as the index of dialysis quality is the fact that urea is relatively nontoxic and one of the molecules most rapidly transported between body fluid compartments. 65 Urea is a small (60 D), uncharged molecule and transported between fluid compartments through aquaporins. Charged molecules such as sodium (positively charged), phosphate (negatively charged) and guanidine acetic acid (negatively charged) are transported at a much lower rate and some require help with their transport. Bigger uncharged molecules such as β-microglobulin, are also transported slowly between compartments. The slow transport of sodium is particularly important for blood pressure control and dialysis hypotensive episodes during short sessions with a high ultrafiltration rate (UFR). Water transport is dependent on sodium transport, but transport of other small, uncharged molecules is much faster than that of charged molecules ( Figure 7 ). Uncharged molecules are transported fast in membranes of body compartments through ultrasmall pores (aquaporins) permeable to carbon dioxide (AQ1), urea, and glycerol (AQ3, AQ6, AQ7). Urea transporters (UT2, UT11) also facilitate transport of neutral molecules. Charged molecules, even small, are transported slowly between body compartments with the help of pumps like Na + /K + ATPase (adenosine-triphosphatase). Transport of other real uremic toxins, such as phosphorus, guanidines, and beta-2 microglobulin is similar to that of sodium and water (not to urea), because they are bigger molecules. Water between body compartments is transported through aquaporins, depending on sodium transport. Transport Figure 6 The derivation of Kt/V assuming that urea generation (G) and change in urea distribution volume (dV) are both = 0 (by the way, this assumption is not completely true as both values are changing: G is increasing and dV is decreasing). During dialysis change of urea concentration over change of time equals the slope constant (−k) times concentration. Slope constant equals urea clearance (K) divided by urea distribution volume (V). By integer exponentiation the concentration at any time (t) may be written as C = C 0 × e -Kt/V . Taking natural logarithm (ln) of both sides of this equation, we get
is called urea reduction ratio (URR).
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of water through dialysis membrane is independent of sodium transport.
RESIDUAL RENAL FUNCTION
In the past, residual renal function was considered important for dialysis prescription. 38, 39 Twardowski reported that patients with urine output over 500 mL/24 hours could achieve clinically adequate dialysis in 12 hours per treatment based on twice-weekly schedule; however, patients with lower urine output required three or more dialysis per week. 23 The residual renal function measured by creatinine clearance was also correlated with clinical status in patients dialyzed twice weekly for 12 hours in each session, but the correlation was inferior to that found for simple urine output. Residual renal function is also considered as very important in peritoneal dialysis. Bargman et al. 66 reanalyzed the CANUSA study results and found that the relative risk of death was related to the glomerular filtration rate and independent of peritoneal creatinine clearance. When the 24-hour urine output was added to the Cox proportional model, urine output was found to be strongly associated with the relative risk of death (and the correlation with glomerular filtration rate vanished). It appears that in patients requiring dialysis, the 24-hour urine volume correlates better with clinical status and mortality than glomerular filtration rate. Therefore, it appears that for residual renal function assessment, a simple urine collection is better than measurements of glomerular filtration rate. In the CANUSA study, for each 250 mL of 24-hour residual urine volume, there was a 36% decrease in relative risk of death. 66 In the NCDS [53] [54] [55] and in the K/DOQI Clinical Practice Guidelines, 67 residual renal function was ignored as relatively insignificant in comparison with the efficiency of hemodialysis. However, the recent NECOSAD report clearly indicates that residual renal function is an important predictor of survival in HD patients. 68 Not surprisingly, the same study found that fluid balance is an important variable in hemodialysis treatment besides being a predictor of mortality. 68 In another study, the presence of residual renal function was found to be protective against mortality. 69 Some patients preserve residual renal function extremely well for years. 23 A recent study showed that the decline rate of residual renal function in hemodialysis patients particularly in older patients, is slow, compared to the rates reported for peritoneal dialysis patients. 70 Therefore, the reports on the relationship between morbidity and mortality, and dialysis efficiency parameters during the initial years on dialysis are confounded if the results are not stratified according to the residual kidney function. We have not found any data indicating the reason of the discrepancy between glomerular filtration rate and urine output on the influence on mortality in dialysis patients. One may speculate that renal tubules reabsorb lower percentage of sodium, phosphorus and other uremic toxins filtered in glomerulus at lower creatinine clearance. Removal of sodium and water is particularly important.
MAJOR PROBLEMS WITH SHORT (HIGH BLOOD FLOW) DIALYSIS AND THE NEED TO CHANGE A PARADIGM
Problems with short Dialysis (small t)
Early reports
As we mentioned above in the first paper on shorter dialysis, Schupak and Merrill 31 reported a markedly higher rate of hypertensive problems compared to the early reports on longer dialysis. 18, 19 The French Dialysis Registry reported a gradual decrease in hemodialysis duration during the 1970s and a higher rate of hypotensive episodes 71 In 1983, the European Dialysis and Transplant Association reported "the proportion of deaths in the Federal Republic of Germany was twice as high in short dialysis." 72 An early warning that a short duration of dialysis was associated with multiple problems related to water and sodium retention came in the report by Sellars et al. 73 Exchangeable sodium was significantly increased with short dialysis, and more patients required antihypertensive drugs. A similar caution was sounded from Germany in the report by Wizemann and Kramer 74 in 1987. They did not observe any significant differences in serum biochemistry between short (2.5 hours) and long dialysis (4 hours), except for serum phosphate, which was lower during longer dialysis. However, weight gains were higher, blood pressure control was worse, and hypotensive episodes were markedly more frequent with shorter dialysis. 74 Although short dialysis was introduced in Europe, it soon crossed into United States. According to Wizemann and Kramer, "In contrast to AIDS, the virus of short duration dialysis has crossed the ocean from the old world and has invaded the United States." 74 By the end of 1980s, in the United States, 60% to 70% of patients had total weekly dialysis time less than 11 hours. Even though the European dialysis facilities were first to introduce short dialysis, (in the 1980s and 1990s), most centers practiced longer dialysis sessions than those in the United States. Japanese centers practiced the longest dialysis sessions. Some centers in Europe either never practiced short dialysis 75 or returned to longer dialysis after discouraging long-term results. 74 
Fluid compartment volumes during hemodialysis
Salt and water are distributed in at least three compartments: intracellular, interstitial, and plasma. It may be compared with the multiple pool system in a large natatorium. Let us imagine that the natatorium is composed of three pools: a large (competition pool), a middle pool, and a little pool. The large pool represents the intracellular water, the middle pool the interstitial water, and the small pool the plasma. Now, let us imagine that these three pools are connected through hoses (see Figure 8A , B), the large pool with the middle pool through a smalldiameter hose and the middle pool with the small pool through a slightly bigger hose. Finally, let us imagine that the water from the small pool is removed very rapidly (like in hemodialysis from the plasma through a high-flux dialyzer). The water from the middle pool cannot refill the small pool, so the volume of water in the small pool rapidly decreases. This is exactly the situation during short, high-rate ultrafiltration hemodialysis (see Figures 8A and 9 ). Salt and water are removed quickly from the plasma (larger hose Figure 8A ) and move slowly from the other compartments (pools). This rapid removal of salt and water causes a rapid decrease in plasma volume and lowers blood pressure, leading to intradialytic hypotension (IDH). In mild cases the patients feel weak, but severe depletion of salt and water may lead to hemodynamic compromise and altered sensorium (crashes). The excess salt and water remains in the other compartments (pools), and is returned to plasma during several hours after dialysis is completed. Immediately after dialysis, this low plasma volume causes severe thirst, weakness, and other symptoms similar to those following the heavy use of alcohol 
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(postdialysis hangover), such as weakness, nausea, dizziness, lethargy, anxiety, and headache. Some patients tolerate rapid ultrafiltration better than others, probably because their salt and water intercompartmental transfer is faster. For many patients the first stop after dialysis is a water fountain to replenish decreased blood volume. It is obvious that the situation is aggravated by higher interdialytic weight gain and shorter dialysis. In such situations, the ultrafiltration rate is set higher and the volume depletion in the blood compartment is more severe at the end of dialysis, and crashes are worse. Occasionally, patients ask to eliminate this extremely uncomfortable last hour of dialysis; however, it is impossible to eliminate the last hour of dialysis. If the dialysis time is cut, the situation is much worse during the next dialysis. It should be clear the last hour of dialysis is better tolerated if the time between the first and the last hour of dialysis is longer, such as in a long, 8-hour hemodialysis (see Figures 8B and 10 ). In such cases, the removal of sodium and water (ultrafiltration rate) from the small pool is slower (much smaller hose Figure 8B ), the refill from the middle pool is sufficient to prevent volume depletion, and the middle pool is refilled from the large pool during dialysis. After such procedures, the patients feel well during and immediately after dialysis, without crashes and hangovers.
High mortality
In the United States, the relative mortality risk was about 20% higher in patients receiving a dialysis duration of <3.5 hours compared to those with treatment for >3.5 hours. 76, 77 The annual mortality in US patients has increased from 10% to 25% from 1970 to 1988, but has remained stable at around 10% in Japan. 78 During the period 1982-1987, hemodialysis mortality in the United States was 22% higher than in Europe and 40% higher than in Japan 79 and the duration of dialysis was 23.5% shorter in the United States than in Europe and 40% shorter than in Japan. 80 The experience in Tassin, France, clearly indicates that longer dialysis (8 hours thrice weekly) than is usual in the United States, improves patient survival. 81 When comparing the survival of US patients to those dialyzed in Tassin, it is in the older age group that the difference is particularly pronounced. While the risk of death is two times higher in the United States in the patients younger than 45 years, it is 12 times higher in patients older than 65 years. 81, 82 This finding is thus similar to Japan.
US comparison, where the relative risk of death in the United States also markedly increases with the age of the patients. 79 The results from the Japanese dialysis registry 83, 84 showed that shorter dialysis increases death rates. In Europe, Valderrábano 85 reported a lower gross mortality rate in patients who were dialyzed for more than 12 h/wk as compared to those dialyzed for <12 h/wk; the difference in mortality was particularly considerable in patients over 65 years old. Changes of fluid compartment volumes during short, high-rate ultrafiltration hemodialysis. Salt and water are removed quickly from the plasma and move slowly from the other compartments (pools). This rapid removal of salt and water causes a rapid decrease in plasma volume and lowers blood pressure, leading to intradialytic hypotension (IDH). It takes many hours to restore plasma volume after dialysis. Figure 10 Changes of fluid compartment volumes during long, slow ultrafiltration hemodialysis. The removal of sodium and water (ultrafiltration rate) from plasma is slower, the refill from the interstitial compartment is sufficient to prevent volume depletion, and the interstitial compartment is refilled from the intracellular space shortly after dialysis. After such procedures, the patients feel well during and immediately after dialysis, without crashes and hangovers, body fluid compartments are normalized within 24 hours. In the beginning, this index was supposed to be >0.95 then, following the publication of the paper by Gotch and Sargent 55 it was established at 1.0. Shorter time was compensated by more efficient dialyzers and increased blood flow through the dialyzer. Weekly dialysis time decreased to 8 hours and mortality rose to 25%, particularly after the results were published in 1983 and 1985. Originally the index of 1.0 was considered as sufficient, but then there were some reports that this index should be slightly higher resulting in a recommended spKt/V urea of 1.3. Data from the European and Japanese registries indicated much better survival in association with longer weekly time on dialysis in Europe and Japan. During a conference in Dallas in 1989, 86 several presentations indicated that the difference in mortality was not related to the patient mix or other factors but shorter dialysis time in the United States. 87 After these results of observational studies, a goal Kt/V urea index of 1.2-1.3 was suggested. Because it was impossible to increase blood flow so the time of dialysis was slightly increased. Even small increase of dialysis time decreased mortality but dialysis time was still about 10 h/wk ( Figure 11 ). In 1997, the National Kidney Foundation-Dialysis Outcomes Quality Initiative (NKF-DOQI) developed guidelines for improved patient outcomes and survival by providing recommendations for optimal clinical practices. 88 Adequacy of dialysis was established as a spKt/V urea of 1.2 (single-pool) for all HD patients dialyzed thrice weekly, regardless of age and comorbid conditions. To guarantee the minimum dose of 1.2, a value of 1.3 was recommended as a prescribed minimum. 88 In 2000, the NKF K/DOQI update 67 reiterated an adequacy spKt/V urea target of 1.3 (single-pool) and eKt/V urea of 1.05 (doublepool or equilibrated). All these reports stimulated a discussion on whether the recommended Kt/V should be increased over 1.3. This dilemma led to the second large NIH-sponsored randomized controlled trial on HD outcomes, the HD (HEMO) study. The results were published in 2002. 89 Out of 2677 screened patients, 1846 were randomized between March 1995 and October 2000. Patients who could not achieve an eKt/V urea of more than 1.3 within 4.5 hours were excluded. The time of dialysis in the standard-dose group was 190 AE 23 minutes and in the high-dose group 219 AE 23 minutes. Dialyzer blood flow in the low-dose group 311 AE 51 mL/min and in the high-dose group was 375 AE 32 mL/min. Single-pool and equilibrated Kt/V urea were 1.32 AE 0.09 and 1.16 AE 0.08, respectively, in the standard-dose group. In the high-dose group, these values were 1.71 AE 0.11 and 1.53 AE 0.09, respectively. The conclusion of this study was that "patients undergoing hemodialysis thrice weekly appear to have no major benefit from a dialysis dose higher than that recommended by current US guidelines." It is worth noting that the higher dialysis dose was achieved by a 21% increase in blood flow rate and 15% increase in dialysis time. Taking these facts into account, the conclusion of the HEMO study should have included "if the higher dose is achieved mainly by increased dialyzer blood flow." Contrary to the numerous observational studies showing that longer dialysis time is beneficial for the dialysis outcomes, 85, [90] [91] [92] [93] there is no study showing that the higher dialyzer blood flow is not detrimental to the Figure 11 Weekly dialysis time and mortality in the United States from 1970 to 2012 based on United States Renal Data System report from 2013. In 1970s, the weekly dialysis time was 20 hours and mortality 10%. Dialysis time shortened rapidly to 8 h/wk and mortality rapidly increased reaching almost 25% in 1985 after National Cooperative Dialysis Study suggested a Kt/V of 1.0. There were some small changes in dialysis time after reports that the Kt/V should be increased to 1.3. It was impossible to increase "K," so "t" was slightly increased to 10 hours followed by a slight drop in mortality. HEMO Study did not have much influence on dialysis time and mortality. However, several publications highlighted the importance of longer dialysis time which increased slightly and the mortality decreased, particularly after DOPPS study in 2006. Very impressive correlation between ultrafiltration rate and mortality was published in 2011. [Color figure can be viewed at wileyonlinelibrary.com]
The need to shift the focus to sodium removal in dialysis patients Hemodialysis International 2018; 22:S29-S64 S43 outcome on dialysis. As a matter of fact, at least one study indicated that excessively negative prepump negative pressures, related mainly to higher dialyzer blood flow, lead to increased hemolysis. 94 Increased hemolysis during dialysis cannot be considered harmless. It is possible that the 21% increase in dialyzer blood flow may have negated the benefit of the 15% increase in dialysis time. The results from the Japanese dialysis registry 83 including over 50,000 patients showed a time of dialysis below 5 hours as an important predictor of death. Therefore, combining "K" and "t" for the measurement of dialysis dose is inappropriate. In our opinion, the HEMO study committed a Type III statistical error-asking the wrong question and achieving the correct answer: if higher Kt/V is achieved mainly by increased blood flow (K), the beneficial effect of such an increase in the Kt/V may not be realized.
A study by DOPPS 95 determined that (1) the duration of an HD session is independently associated with a lower mortality risk after adjustment for case mix, dialysis dose (Kt/V), body size measures and indicators of nonadherence ( Figure 12) ; (2) delivering a high Kt/V over longer treatment time (TT), up to 270 minutes, is of greater value than delivering the same Kt/V over shorter TT, and (3) UFR >10 mL/h/kg body weight is independently associated with higher risk of both intradialytic hypotension and mortality. [Interestingly, Flythe et al. 96 calculated correlation between ultrafiltration and mortality based on HEMO study ( Figure 13 ) and found rapid increase in mortality if ultrafiltration increases above 10 mL/h/kg.] Statistical adjustments were made for patient demographics, comorbidities, dose of dialysis (Kt/V), and body size. The association was present in United States, Europe, and Japan, but was most pronounced in Japan. A synergistic interaction occurred between Kt/V and treatment time (P = 0.007) toward a mortality reduction. Every 30 minutes longer hemodialysis was associated with a 7% reduced relative risk of mortality. In 2007, Twardowski had a debate with Frank Gotch, one of the creators of the Kt/V concept, in Austin, Texas. 97 Gotch questioned this correlation arguing that according to this correlation at some high weekly dialysis time the mortality would drop below zero. Twardowski's counter argument was that it is not justified to extend the correlation beyond the observation limit. Although Dr. Gotch, our opponent in the debate, could not agree completely with Twardowski, he admitted that administering dialysis over longer periods of time is important for better control of fluid status and blood pressure. When we look at Figure 11 it seems, that with 14 hours of dialysis on 3 times weekly schedule the mortality in the United States would fall to 14% (two lines would cross) and with 17 hours the mortality would drop to 10% as it was in 1970 with dialysis time 20 h/wk (but with worse dialyzers). This is only speculation, however, it would be valuable to increase weekly dialysis time to 14 hours and reassess.
Intradialytic hypotension and duration of dialysis lntradialytic hypotension (IDH) occurs in 25% to 50% of short, thrice-weekly hemodialysis treatments in the United States. The detrimental effect of IDH is being increasingly recognized as an important factor in the increased relative risk of death due to acute coronary syndrome, and arrhythmias. 98 Moreover, arteriovenous blood access frequently clots during a hypotensive episode because sudden decreases of blood flow through the fistula. A study from Hungary 99 found higher mortality in patients with frequent episodes of intradialytic hypotension as compared to patients without hypotensive episodes. Patients without hypotensive episodes had longer dialysis duration and lower ultrafiltration rates. Older patients and patients with diabetes mellitus and coronary artery disease were more likely to have hypotensive episodes. If age and comorbidities were included in the multivariate proportional hazard regression model, there was no independent effect of frequent hypotensive episodes on mortality. A randomized crossover study from Marseille, France, showed significantly higher rates of intradialytic hypotension and postdialysis orthostatic hypotension in 4-hour treatment time compared to 5-hour treatment time, and the difference was particularly pronounced in patients with age over 65 years. 100 Dialysis hypotension occurs because a large volume of blood water and solutes are removed over a short period, exceeding the plasma refilling rate, and reduction of venous capacity. 101, 102 Short dialysis is associated with high-speed ultrafiltration and rapid removal of small molecules, thus swiftly depleting plasma volume. In a study by Ronco et al. 103 ultrafiltration rates of 0.3, 0.4, 0.5, and 0.6 mL/min/kg were associated with approximate rates for IDH of 8%, 15%, 26%, and 60%, respectively.
Stratagems to reduce IDH without prolonging dialysis duration
Although the K/DOQI Guidelines 67 and others 98, 101, 102 admit that to avoid IDH the ultrafiltration rate should not exceed the refilling rate, there is no stress on the lengthening of dialysis sessions, the simplest way to avoid the problem. Instead, multiple maneuvers have been applied to increase the plasma-refilling rate and decrease venous capacity such as: isolated ultrafiltration, 104 high dialysate osmolality, 48, 105 bicarbonate based dialysate instead of acetate, 106,107 lowered dialysate temperature, 108 and higher dialysate ionized calcium. 109 Rapid lowering of serum potassium during dialysis and high dialysate magnesium were also considered as factors augmenting hypotensive episodes. 102 Finally, predialysis withdrawal of blood pressure medications and/or use of blood pressure-rising drugs, such as ephedrine, fludrocortisone, caffeine, and midodrine have been recommended. 110 The most popular recent method of preventing IDH is ultrafiltration and sodium profiling. Although a multitude of approaches has been tried, 111 the most common was application of a high ultrafiltration rate and high sodium concentration at the beginning of dialysis with a gradual or stepwise decrease in dialysate sodium concentrations and ultrafiltration rates throughout the dialysis session. 112 Whereas short-term studies showed improvement in the incidence of hypotensive episodes, a careful study of sodium balance showed that improvement was related to a positive sodium balance, leading to chronic volume overload, hypertension, myocardial hypertrophy, and increased cardiovascular mortality. 113, 114 In addition to an increased mortality with rapid ultrafiltration, a recent DOPPS 95 also showed markedly higher odds of IDH episodes in patients with an ultrafiltration rate of >l0 mL/h/kg.
Blood pressure control and duration of dialysis
Hypertension occurs in 90% of patients starting hemodialysis and persists in 70% to 90% of hemodialysis patients in the United States. 115 In the large, multicenter Hemodialysis (HEMO) Study, more than 70% of patients were hypertensive by Joint National Committee on Prevention, and Treatment of High Blood Pressure (JNC VI) guidelines, and almost 75% required antihypertensive medications. 116 This is contrary to the situation in the late 1960s, when strict control of true dry body weight was practiced and the majority of patients did not require antihypertensive agents. 117 There is a consensus that most patients on dialysis have volume-dependent hypertension. Only a small proportion of patients have vasoconstrictive hypertension requiring bilateral nephrectomy in the past 117 or blood pressure medications at present. The problem is how to achieve normovolemia and blood pressure control without medications.
Hypertension is less frequent in Europe and Japan where dialysis time is longer. The lowest mortality related to cardiovascular causes is reported from Centre de rein artificial, Tassin, France 114 where long duration hemodialysis is practiced. Long-term mortality in this center is lower in patients with lower mean blood pressures. In addition, gentle ultrafiltration and proper estimation of dry body weight allow the achievement of good blood pressure control in the majority of patients. 114 Hypotension, in patients dialyzed thrice weekly for 8 hours, is a strong indicator that the patient weight dropped below the true dry body weight. 114 Bernard Charra, a student of Scribner, spent some time in the early 1970s in Seattle, and continued to use the dialysis prescription from Seattle when he returned to settle in Tassin, France. This prescription of 8 hours HD 3 times weekly led to excellent control of blood pressure without blood pressure medications in more than 95% of patients ( Figure 14) . 114 Time of dialysis was gradually increased after start of dialysis from 3 to 8 hours with careful clinical observation of patients, which he learned from Scribner and Robin Eady, a hemodialysis patient who started treatment in Seattle and survived 27 years on home hemodialysis until he received a kidney transplant. 118 The decrease
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of pressure was delayed several weeks after body weight dropped.
Evolution of postdialysis weight and predialysis mean arterial pressure (MAP) at the start of HD in Tassin, France start 3 hours, then within 2 months and 4, 5, 6, 7, and 8 hours thrice weekly
With rapid ultrafiltration, hypotension is dependent mostly on hypovolemia, which occurs long before the dry body weight is achieved. In spite of clear evidence that short dialysis is associated with poor blood pressure control, the blame is commonly put on suboptimal drug therapy, excessive interdialytic weight gains ("patient noncompliance"), and the practice of withholding antihypertensive medications before dialysis. 119 With longduration hemodialysis sessions, blood pressure could be controlled without antihypertensive therapy in 90% to 95% of patients. [23] [24] [25] 114 These patients have volume dependent hypertension. The remaining 5% to 10% of patients has "refractory" hypertension treated with bilateral nephrectomy in the past; but nowadays, these patients respond to antihypertensive therapy with converting enzyme inhibitors. 120 The originator of chronic dialysis, Belding H. Scribner, who practiced long duration dialysis sessions in the 1960s, in recent years forcefully advocated departure from short dialysis and better attention to volume management for blood pressure control. [121] [122] [123] [124] Other groups also advocate longer dialysis sessions for better blood pressure control. 90, 93, 125 A recent randomized crossover study of long (6-8 hours) dialysis thrice weekly at home and short (3.5-4.5 hours) thrice weekly in the dialysis center showed much better control of blood pressure and reduction of hypotensive episodes with longer dialysis sessions. 126 Even moderate prolongation of dialysis sessions from 253 AE 15 to 273 AE 25 minutes together with strict control of sodium balance over 3-4 months, allowed control of blood pressure in 10 of 16 patients with "dialysis-resistant" hypertension. 127 The K/DOQI Guidelines did not recommend duration of dialysis as an independent measure of dialysis adequacy. After discussing all arguments for and against the importance of dialysis duration, the K/DOQI Work Group could not reach consensus on this subject and did not include it in the final recommendations. 67 Some Work Group members felt strongly that the time of dialysis should not fall below 2.5 hours, but duration of dialysis over 4 hours was not recommended. 67 However, we see no good explanation for why duration for dialysis is dismissed as unimportant. On the contrary, we feel that there is good evidence to advocate the role of longer dialysis in lowering blood pressure in dialysis patients.
Blood pressure control by dietary measures, low dialysate sodium, and a "lag phenomenon"
The possibility of controlling blood pressure in a renoprival state by drastic reduction of dietary salt intake with "rice diet" was first shown by Kempner 128, 129 in the 1940s. It was later shown that the beneficial effect of the "rice diet" on hypertension was related to the lowering of plasma volume and extracellular fluid space. 130 In the 1960s, it was considered mandatory to restrict dietary salt intake in hemodialysis patients to control blood pressure. This restriction was combined with long dialysis sessions and relatively low dialysate sodium. The achievement of blood pressure control was very gradual. This was not surprising for the hemodialysis pioneers as this phenomenon was already observed by Kempner 128, 129 in the 1940s. In the first patient on a "rice diet" containing less than 500 mg/d of salt, blood pressure was lowered gradually from 230/145 to 135/90 mmHg in 8 weeks. 128 Even achievement of dry body weight does not lead immediately to control of blood pressure because the relationship between extracellular volume status and blood pressure is not simple and linear, but complex because of a lag of several weeks between the normalization of the time averaged extracellular volume and the decrease in blood pressure ("lag phenomenon") 121 ( Figure 14) . The exact pathophysiology of the lag phenomenon is not clear. It is likely that this may be caused by the retention of circulating factors, such as asymmetric dimethyl-L-arginine, a potent inhibitor of nitric oxide synthesis and Na+K+-ATPase inhibitors that may remain elevated because of a large volume of distribution and ineffective removal. 131, 132 Elevated sodium may remain in the arterial smooth muscles and be responsible for vasoconstriction. It may take several weeks of normovolemia for the intracellular sodium to escape. Regardless of the mechanism, the normalization of blood pressure by volume control is tricky, requires patience and a good understanding of the problem. 114, 121, 131, 132 Several groups have tried to lower extracellular volume and blood pressure without lengthening dialysis duration by dietary measures and low-dialysate sodium. 133 In eight patients, Krautzig et al. 134 tried a regime of gradual lowering of the dialysate sodium concentration from 140 to135 mEq/L at a rate of 1 mEq/L every 3-4 weeks and restricting dietary salt intake while maintaining dialysis duration of 4-5 h/session. It is worth stressing that dialysis duration in the above cohort was longer that than practiced in the United States. The authors reported lowering of blood pressure in these patients with a possibility of stopping blood pressure medications in four patients and only a moderate increase in the frequency of cramps during dialysis. The control of extracellular volume by a low sodium diet without prolongation of dialysis duration and low dialysate sodium is difficult; it increases intradialytic symptoms and requires a very strict adherence to an unpalatable diet.
In advanced kidney failure, all mechanisms intended to increase renal sodium removal are inefficient or futile. In complete anuria, the sodium balance must be achieved via dialysis and ultrafiltration. Scribner's attention in initial chronic dialysis patients was directed toward fluid and electrolyte disturbances during dialysis treatment. He saved the life of Clyde Shields, the first chronic hemodialysis patient, from malignant hypertension by ultrafiltration over 76 hours. In the discussion of the preliminary report on intermittent hemodialysis, Scribner et al. 3 indicated that, "as in the nephrectomized dogs, hypertension appears to be influenced by the size of the extravascular space. The combination of dietary sodium restriction and ultrafiltration during dialysis permits regulation of extracellular volume. In time, it may be possible to clarify the importance of the size of the extracellular space in the etiology of hypertension and the effect its size may have on modifying the response to antihypertensive therapy." Many years later, Scribner, in his memoir on the beginning of intermittent dialysis, alluded to the treatment of malignant hypertension in his first patient by ultrafiltration as soon as he became normotensive and remained so the rest of his life. "This experience convinced us that the key to treatment of hypertension in dialysis patients was adequate control of the extracellular volume, a principle that proved to be of immense importance from that point on." 7 In the late 1960s, the term "dry body weight" was introduced and defined as "no clinical evidence of edema and optimal body sodium content and volume of water." 117 As mentioned at the beginning of this article, in the 1960s and early 1970s, centers using long dialysis sessions combined with low-salt diets achieved control of hypertension without antihypertensive medications in over 90% of dialysis patients. 18, 20 Since the late 1970s, shortening of dialysis time has led to a resurgence of hypertension and increased mortality. 73 With short dialysis, blood pressure could not be controlled by control of extracellular volume, and the definition of dry body weight was gradually redefined as the lowest weight a patient can tolerate before experiencing hypotension or symptoms. 135 However, with rapid ultrafiltration, hypotension is dependent mostly on low plasma volume, which occurs long before the dry body weight is achieved. Consequently, with short dialysis, true dry body weight cannot be achieved.
PROBLEMS WITH HIGH SMALL SOLUTE CLEARANCES (LARGE K)
Blood flow and efficiency of Dialysis Short dialysis with fixed Kt/V urea leads to maximization of dialysis efficiency by using higher efficiency dialyzers and high blood and dialysate flows; however, the influence of blood flow on the efficiency of dialysis is markedly lower than dialysis time. Removal of MMs (including phosphorus) is only slightly dependent on blood and dialysate flows, 40 so compensating shortened dialysis time by increasing blood flow is not effective. This is not only related to the slow diffusion of these molecules through the membrane, but also to multicompartmental behavior, that is, slow diffusion from the extravascular space to the plasma. 136 This process may be compared to the poor "plasma-refilling rate" of water and sodium in high ultrafiltration rate hemodialysis. It is worth realizing that even for removal of small molecules, an increased time of dialysis is more effective than increased blood and dialysate flows, because spKt/V urea (single pool) is directly proportional to dialysis time, but K is exponentially, not linearly, proportional to blood and dialysate flows.
High blood flow rates and retrofiltration
The introduction of ultrashort dialysis treatments with high blood flow and high flux dialyzers brought other The need to shift the focus to sodium removal in dialysis patients Hemodialysis International 2018; 22:S29-S64 S47 unexpected, undesirable effects, namely back filtration or retrofiltration of dialysate to the blood compartment. 137, 138 Claudio Ronco, a noted expert on hemodialysis and peritoneal dialysis 139 explained that back filtration (retrofiltration) is particularly pronounced with long dialyzer and the high flows of blood and dialysate 140 ( Figure 15 ). The consequence of bacterial product delivery from the dialysate to the blood stream is an acute phase reaction with consequent chronic inflammation, protein-energy malnutrition, and accelerated arteriosclerosis constituting the well-described malnutrition-inflammation-arteriosclerosis syndrome. 141, 142 High blood flow rates and blood access problems Short dialysis with fixed Kt/V urea leads to maximization of dialysis efficiency by using higher efficiency dialyzers and high blood and dialysate flows. According to the Dialysis Outcomes and Practice Patterns Study (DOPPS), in the United States, the mean dialysis duration of 213 minutes is the lowest of the seven nations participating in the analysis, and the prescribed blood flow rate of 401 mL/min is the highest. 143 The requirement of high blood flow increases demand on blood access. There are major differences in blood access use between Europe and the United States in both genders and all age groups in patients with and without diabetes. In addition, survival of AV fistulas is better in Europe than in the United States. 144 It is our suspicion that the differences are related, at least in part, to the differences in required blood flow. For instance, primary arteriovenous fistula providing blood flows of 300 mL/min may be considered appropriate for long dialysis (dialysis duration of at least 5 hours with a thrice weekly schedule), but may be considered inadequate for short dialysis (<5 hours). Such a fistula may be then abandoned and an AV bridge graft created instead [personal observation, Twardowski].
Even fistula providing blood flows of 350 mL/min are in jeopardy because of repeated attempts to achieve higher blood flows using tourniquets and other maneuvers. With these attempts, the intima of the fistula is damaged by suction of the inflow needle, and the survival of the fistula is shortened. Hypotensive episodes suddenly reduce fistula blood flow and predispose the fistula to clotting. High blood flow requires large needles, low negative prepump pressure, and high postpump pressure. These flows and pressures cause higher damage to red and white blood cells. 94 High hemolysis is obviously detrimental. Large needles are worse for fistulas especially if buttonhole method of needle insertion is used. 145 If intravenous catheters are used as blood accesses, large catheter lumens are required to achieve high blood flows. However, a large diameter catheter fits the vein too tightly and predisposes the vein to damage of the wall, thrombosis and stenosis. 146 Thus, the requirement of very high blood flow may be a contributing factor to poor blood access results in the United States.
ADVANTAGES OF LONG DIALYSIS (LONGER T) Dialysis personnel and patient position during dialysis
From the above discussion, the advantages of long dialysis to the patients are obvious: better tolerance of dialysis, better control of blood pressure, better removal of MMs, and sodium, better rehabilitation, and longer survival. The average ratio of patients to dialysis personnel is 3-4 to 1 in the United States. Because of better tolerance of dialysis with fewer hypotensive episodes, the same ratio in Tassin is 6 to 1. 114 Patients also tolerate dialysis better because they stay in bed ( Figure 16 ). All of Twardowski patients in Poland stayed in beds during hemodialysis. A similar practice is observed in Japan, Germany, Italy, and Britain. In the United States most patients sit in chairs during dialysis ( Figure 17 ). When Twardowski came to the United States in 1976, he was surprised that patients sit in chairs, particularly with short dialysis. The explanation that was offered was that the sitting position offered a psychological benefit to the patients since the patients would feel more like being in the clinic and not in the hospital. Sitting in a chair is associated with transfer of extracellular water to legs and predisposes to hypotension much more than in patient recumbent in beds. Thus, the financial disadvantage of longer dialysis in bed may be offset by reduced staff requirement needs. Long dialysis sessions may be performed at home without increased cost to the providers.
PROBLEMS WITH V (UREA DISTRIBUTION VOLUME)
Using the same Kt/V index for large and small patients the K and t have to be adjusted. Depner et al., 147 based on the HEMO study, found lower overall mortality in patients with higher body weight, higher body mass index, and higher body water content determined by the Watson formula. Males had higher body size than females with a higher V. For higher dose dialysis, the average time of hemodialysis in males was 231 minutes, 200 minutes for lower dose dialysis (15.5% increase). Blood flow for higher dose dialysis was 381 mL/min, 330 mL/min (16.6% increase) for lower dose dialysis. In females, the average time for higher and lower dose dialysis was 210 minutes, and 182 minutes, correspondingly (15.3% increase). The blood flow for higher dose dialysis in females was 367 mL/min, 295 mL/min for lower dose dialysis (24.4% increase). K × T (Urea) for high dose in males was 59.6 L for high dose dialysis in males and 45.5 L (30.98% increase) for low dose dialysis. The corresponding values for high and low dose dialysis in females were 51.7 L and 38.2 L (35.3% increase). The mortality improved in females with higher Kt/V, but not in males. It is obvious that it is much easier to achieve 
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higher Kt/V with lower V. A very small urea distribution volume (V) will provide large Kt/V urea in malnourished patients, even if their dialysis duration is short and dialyzer clearances are low. One can imagine that monitoring only Kt/V urea may predispose the patients to lose appetite, and become malnourished while still maintaining this index of dialysis adequacy, despite continuously losing weight and urea distribution volume (V). The Kt/V formula is misleading and should be abandoned as a measure of dialysis quality. Would any aircraft pilot use an altimeter showing the wrong altitude?
KT/V UREA SHOULD NOT BE USED AS A MEASURE OF DIALYSIS QUALITY
The acceptance of this index was based on insufficient data and their false interpretation. In the NCDS study the tendency toward lower morbidity with longer dialysis duration was rejected as statistically insignificant because P was 0.06 (or 0.056) instead of 0.05. However, the power of this study was low because of an insufficient number of patients, short study duration (52 weeks) and an utter disregard of residual renal function, which must have been substantial as many patients were of short vintage. It is worth repeating that the absence of evidence is not the evidence of absence. This index undoubtedly led to rejection of the importance of dialysis time and may have contributed to poor outcomes on HD in the United States. As more efficient dialyzers were developed, the length of dialysis decreased to three and even to 2 hours. Annual mortality of HD patients in the United States rose in the 1970s, and, after the results of NCDS were published, reached 245.6/1000 patients at risk in 1988. 148 Chertow et al. noted that "It is difficult to conclude from the NCDS that session length is not meaningful; … one might argue that NCDS session length P = 0.06 was the most significant (important) 'nonsignificant' (statistically) effect in the history of dialysis research." 149 Combining dialyzer urea clearance (K), dialysis duration (t), and urea distribution volume (V) in one formula and accepting this formula as a measure of dialysis adequacy has brought about adverse consequences. The formula suggests that it is possible to decrease t as long as K is proportionately increased, but this is not true. For instance, increasing dialyzer urea clearance (K) may compensate for shorter dialysis time (t) regarding urea removal, but it cannot compensate for the dialysis tolerance depending on the rate of ultrafiltration, nor has it reflected removal of bigger molecules and charged molecules like sodium.
FREQUENCY OF HEMODIALYSIS HIGHER THAN THRICE WEEKLY
As mentioned previously in the section "Attempts to shorten dialysis duration," there were efforts in the 1960s and early 1970s to shorten dialysis for reducing the total weekly time on dialysis and be able to increase the number of treated patients. The first attempt was tried in Parma by Vicenzo Cambi in patients who were dialyzed on Kiil dialyzers for 27 h/wk and were gradually switched to coil dialyzers and dialyzed 3 hours every other day for an average of 11.2 h/wk. 32 The patients had good biochemical control, but in a subsequent paper they mentioned problems with blood pressure control to such a degree that two patients had to have bilateral nephrectomies. 33 This was the first attempt to dialyze every other day, but this method was not popular as most dialysis units did not work on Sundays. This had been used in France. 150 In 2000, there was the first paper on every other day dialysis (EODD) in the United States. 151 It started with a very convincing introduction for the reason of this method: "The Bible says that God decreed the 7-day week. Unfortunately, it has not been good for hemodialysis patients. A recent study of the septadian rhythm of deaths in hemodialysis patients, based on analysis from the United States Renal Data System (USRDS), showed an uneven distribution of sudden and cardiac deaths in hemodialysis patients; whereas there was an even distribution of sudden and cardiac deaths in peritoneal dialysis patients. 152 Hemodialysis patients were more likely to die suddenly or of cardiac causes on Monday or Tuesday. It is clear from this study that the intermittent nature of hemodialysis, particularly long periods without dialysis over the weekends, predisposes to increased mortality after the weekend; whereas the continuous or quotidian nature of peritoneal dialysis does not predispose to such a phenomenon." Twardowski used this method in his patients on home hemodialysis. It could not be used in our center because the center did not work on Sundays. The authors concluded the paper with a statement: "We believe that EODD should be widely available so that both physicians and patients have this option to improve dialysis dose, blood pressure control, and survival. In return, an immediate and obvious improvement in patients' wellbeing would recruit more patients to EODD. Further, we believe, the increased cost would be more than offset by decreased hospitalizations and treatment of complications. Cost savings would be realized immediately because of reduction in emergency treatments of pulmonary edema on Sundays and Mondays. Finally, no expensive, doubleblind, national study would be necessary to validate EODD." This pattern is now becoming popular in the United States but in home hemodialysis not in center. 153 This method allows dialyzing patients with a gentler, slower and more frequent prescription eliminating the "Two Day Killer Gap."
Pierratos et al. 154 described the early period of daily or more frequent dialysis in 1960s and 1970s. They reported the use of daily dialysis in acute renal failure by Paul E. Teschan 155 (this had tremendous influence on the adoption of frequent hemodialysis in chronic renal failure). The story of Teschan's achievements was presented in a laudation in 1998. 156 The history of the development of prophylactic daily dialysis was described in this laudation. Twardowski used his method of treatment in crush syndrome in miners. 157 From 1964 to 1971, he treated 11 patients and achieved cure in 9 (81.8%) of patients, which we believed were results of prophylactic and frequent (usually daily) hemodialysis. The first use of daily hemodialysis for chronic renal failure is credited to DePalma et al. in 969. 158 They dialyzed 7 patients 5 times a week for 4-5 hours per session on Kiil dialyzer, but had to abandon the program after 3 years for financial and technical reasons. The next center to do 5 times weekly dialysis was Bologna, Italy, under the direction of Vittorio Bonomini. 159 They dialyzed six patients 3-4 h/session and noticed improvement in anemia, hypertension, neuropathy, osteodystrophy, and pericarditis. The story of Professor Bonomini's achievements was described in Laudation in 1998. 160 Professor Bonomini's studies on early, frequent, and efficient dialysis in chronic renal failure, published in the early 1970s, were received with great skepticism. However, as Twardowski remarked in the laudatio, "after a quarter of a century, has the nephrology community embraced his notion that dialysis should be started before the patient becomes severely uremic and malnourished and that dialysis should be carried out frequently, optimally every day?" 160 Pierratos et al. mentioned also our studies of 4 times weekly 6-7 hour dialysis 23-25 and 5 times weekly dialysis for 2 hours in Brooklyn in 1975. 161 In the same year, the reasons for the improvement of the clinical status with the more frequent HD were described by Kjellstrand et al. 162 In 1998, Carl Kiellstrand published a paper on early development of daily hemodialysis. 163 Figure 18 (modified from this paper) shows the centers and number of patients from 1967 to 1997. The highest number of patients was in Perugia 164 and Catanzaro, 165 and gradually in other centers in Italy, Canada, United States, Europe, Brazil, and Japan. The development of daily dialysis accelerated in later years because of very good results. Kjellstrand et al. 166 found that survival of patients on short daily hemodialysis in center or in home was 2-3 times better than that of matched thrice weekly hemodialysis patients reported by United States Renal Data System (USRDS). A total of 250 patients were treated at home and 165 in the center.
CLINICAL ASSESSMENT OF DIALYSIS QUALITY
One may ask what index of dialysis adequacy should be used instead of Kt/V urea . It is tempting to give a simple formula, easy to implement and easy for bureaucrats to control. If such a formula were really developed, nephrologists may not be needed in dialysis centers since algorithm guided protocols and dialysis technicians would suffice. We do not believe that such a formula will be developed anytime soon as dialysis is a very complex procedure. The uses of rigid, quantitative guidelines (e.g., spKt/V urea of 1.3 per dialysis) assume that all patients behave identically in response to therapeutic maneuvers, like the mean of the group, but this is not true. 167 Medicine is still an art, not exclusively science; the individual approach assumes that there are differences among patients which require adjustment of the dialysis prescription for each patient based on clinical symptoms and signs. It is better to use clinical judgment instead of misleading formula. During the early years of chronic hemodialysis, the definition of adequate dialysis was based on the two essential goals of dialysis: eradication of signs and symptoms of uremia, and rehabilitation. 18, 23 In the early 1970s, the definitions were based on a mixture of resolution of clinical symptoms and laboratory data 24, 168 This approach of assessing adequacy is subjective, requires very careful monitoring of patients, and is time-consuming, but it is relevant for the individual patient. In this context, we would like to cite Ronco's 169 formula for a general approach to dialysis, MDt/P, where MD is the doctor and t/P is the time spent with the patient.
In the 1970s, it was considered obvious that an absence of uremic symptoms predicted low morbidity and mortality. Does it hold true in the 2000s? The DOPPS study found a strong association between lower scores for the three major components of health-related quality of life and higher risk of death and hospitalizations in hemodialysis patients. 170 In another DOPPS report, physical functioning was better in Japan and Europe than in the United States, where there is the highest mortality. Particularly striking was the high percent of comorbidities related to hypervolemia, such as hypertension, congestive heart failure, and dyspnea in There is another possibility to determine the best method for a particular patient, so called "N of 1" study. 172, 173 This type of study can be performed in a patient with one method of dialysis and if the results are not good the method may be changed to another.
The dialysis in patients should start with short (3 hour) sessions, as established by Charra, shown in Figure 14 114 with gradually increasing time and frequency depending on residual urine output and results. Based on all studies, it seems that most patients with urine output less than 500 mL/day may require 15-17 hours of weekly dialysis time with blood flow of no more that 250 mL/min and frequency of dialysis more than 3 times weekly without the "Two Day Killer Gap." The more frequent the better (e.g., EODD × 5 hours, 4 × 4 hours, 5 × 3.25 hours, 6 × 2.75 hours, 7 × 2.25 hours). Long-night (7-8 hours) dialysis may not require more than 3 times weekly sessions. If buttonhole method of needle insertion is used, patients dialyzed more than 3 times weekly should have more than one (2 or 3) buttonholes for inflow and outflow. 145 The initiation of dialysis is very important. The patient should not start dialysis before having symptoms related to fluid overload or some other clinical manifestations of uremia. Indication to start dialysis based only on creatinine clearance <15 mL/min turned out to be inappropriate, particularly if this clearance was based on blood urea and creatinine alone 174 ; urine output close to a liter per day is a better indicator. It is known that patients starting dialysis very early do not feel any improvement after starting dialysis and were less likely to follow recommendations. Starting with short dialysis the patient should be informed that the dialysis time and frequency may gradually increase depending on urine output, laboratory tests, and symptoms. Obviously, a patient suddenly sent to the hospital with severe uremic symptoms should be dialyzed like having acute renal failure and then gradually switched to chronic dialysis.
HOME HEMODIALYSIS
Home hemodialysis was performed in Seattle on a patient without medical supervision in 1965. 15 Shortly thereafter, the Seattle group developed a technique for storage and reuse of dialyzers. 16 There is some controversy about the first home hemodialysis. Yukihiko Nosé, who was not a physician, claims that he was the first who developed home hemodialysis machine using a washing machine in 1961, treated patient in 1963, and submitted an abstract with Dr. J Mikami to ASAIO but it was not accepted for presentation. 175 Stanley Shaldon strongly opposes this claim and states that three groups from Boston, Seattle and London, working independently, having commenced home hemodialysis in 1964, reported their experience in a meeting in Seattle in 1964. 176 Home hemodialysis was developing very fast in the United States in the second half of 1960s and reached 40% of total hemodialysis patients in 1971. Then, it started to decline rapidly until achieved 1% in 2002. The major problem was lack of machines suitable for easy service at home.
THE STORY OF THE FIRST MACHINE FOR DAILY HOME HEMODIALYSIS
We believe that the first machine for daily hemodialysis was based on the concept Twardowski developed in the 1970s, but was only accomplished after 30 years. The detailed story of the development of this machine was described in a paper published in 2003 177 and in Twardowski's autobiography. 178 The idea of frequent hemodialysis came to Twardowski's mind while he was working on the adequacy of hemodialysis in relation to the frequency and duration of sessions from March 1969 through May 1973. [23] [24] [25] He was impressed with the results of frequent dialysis and predicted that daily dialysis would be the basic form of treatment of uremia. At that time he also reviewed available machines for hemodialysis and summarized their advantages and disadvantages. 179 He thought that for quotidian home hemodialysis a new machine would be necessary. This machine should have several important features. First of all, it should reuse dialyzers and lines to decrease the cost. This was based on his experience with reuse of coil dialyzers with the cuprophane membrane, 180 and RP-6 dialyzers with the polyacrylonitrile membrane. 181 Second, it should prepare dialysis solution from dry chemicals. Third, the machine should automatically prepare itself for dialysis, thus saving time for patients.
The first two features would markedly decrease the storage space at home and reduce waste, thus being friendly to the environment. The third feature would make the machine user-friendly and render a helper inessential. The two elements which Twardowski wanted to include in the overall concept were a tank system, slightly similar to the Travenol RSP machine, and the direct measurement of ultrafiltration which was used in the Rhodial 75 device. 181 He thought that for adequate removal of uremic toxins the tank should have a capacity somewhere between 60 and 100 L. Later, he disclosed his invention to the University of Missouri at the Columbia Office for Patents and Licensing on May 18, 1983 , UM Disclosure No. 83-UMC-027. The university office started looking for a potential licensee and sent an abstract to several companies including Baxter. On May 20, 1983, Twardowski sent a letter to Donald W. Joseph, the company's vice president, suggesting potential cooperation in developing the machine. He was invited to visit them in September 1983 and presented his concept to the group, including engineer Thomas E. Muller. He felt that Mr. Muller and others in the engineering department were in favor of working on the project, but after about a year the Baxter Travenol lost interest No reasons to abandon this project were offered. With no enthusiasm from other companies, the University Office of Patents and Licensing remained reluctant to submit an application. At that time Twardowski was busy with other projects, including a tidal peritoneal dialysis project, on which he was collaborating with a highly innovative advanced systems development manager at Baxter, Rodney S. Kenley. Thus, the idea to develop this machine was put on the back burner.
In December 1988, the 21st Annual Meeting of the American Society of Nephrology was held in San Antonio, TX. Twardowski talked to Rod Kenley during this meeting about his idea of fashioning a machine for use in daily home hemodialysis. They spent about 10 hours talking about it. Rod "bought it" and tried to convince Baxter to start working on the project but with no results. On January 25, 1989, Twardowski had a presentation on tidal peritoneal dialysis at Baxter Healthcare Corporation Headquarters in Round Lake, IL. 182 After this presentation, another round of discussion on daily HD machine was held with the officials at Baxter. However, Baxter remained uninterested in the venture. Twardowski feels that there were two reasons why Baxter did not go ahead with his idea. First, Baxter felt that it was uncertain whether the project would be successful and thus would offer a poor return on their investment. Second, if the project were successful, it might jeopardize the viability of their successful business model in peritoneal dialysis.
Rod advised Twardowski to ask for a waiver of the University's right to his invention disclosed in 1983 and then submit the patent application privately (a patent would make private funding easier to obtain). He received a waiver on June 13, 1989 . Ultimately the application was filed in the United States Patent Office on August 21, 1991, and the patent was issued on August 9, 1994. 183 Based on the initial submission, three more divisional patents were granted. [184] [185] [186] A fifth, very important patent was filed on November 7, 1994, as a division of the previous application but with a new claim related to the method of filling the blood compartment in the dialyzer. This claim was discussed with Rod before Twardowski had submitted his first patent application, so the patent was issued with both (Zbylut J Twardowski and Ramesh Khanna) as inventors. 187 The need to shift the focus to sodium removal in dialysis patients Hemodialysis International 2018; 22:S29-S64
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In the meantime, Rod Kenley founded Aksys Ltd. in 1992 and was able to receive money from venture capital group in 1993. He hired engineers and started to build the machine, which was accomplished in 1999. In the summer of 1999, Aksys obtained an investigational device exemption (IDE) from the FDA, and finished the study in October 2000. Twardowski followed four patients during the trial of daily dialysis: three were anuric and one with urine output over 800 mL/day. The anuric patients claimed a stunning improvement within a week. One anuric patient, seen during dialysis training on Figure 19 , who had years of experience on peritoneal dialysis and hemodialysis, said that after switching to more frequent dialysis on Personal Hemodialysis System (PHD) he felt like his thinking was clearer, not hazy as before for the first time in many years. Only a patient with diuresis did not notice much difference in spite that his chemistries showed substantial improvement. After the clinical trial was completed, the application was submitted to the FDA on January 16, 2001 , and Aksys received the clearance to market the Personal Hemodialysis (PHD) System (obtained 510-k) on March 18, 2002 .
The PHD system (Figure 20 ) 188 combined four machines in one: a dialysis machine, a reuse apparatus, a water treatment appliance, and a device manufacturing ultrapure infusion-quality solution. Hence, there was no need for the delivery of solutions for infusion. The machine was based on the tank dialysis solution system. Eliminating the proportioning system simplified the machine design, and the use of positive pressure ultrafiltration eliminated the need for a deaeration pump. Finally, the closed system allowed direct measurement of the ultrafiltrate. By setting up for dialysis and tearing down after dialysis, the machine saved the patient (or helper) time, and saved money by reusing supplies, decreasing transportation costs, and minimizing storage space. In addition, a very important feature was the almost complete recovery of blood after dialysis using socalled backfiltration, the transfer of dialysate through the membrane and thereby pushing blood from the dialyzer to the patient through both arterial and venous lines.
The most extensive experience with treatments using the PHD was from the Northwest Kidney Centers in Seattle. 189 From 2004 onward, more centers were using the PHD. Ultimately, 35 centers used it for 308 patients in 2006. Dr. Kjellstrand, who saw many patients maintained on the PHD in Seattle, considered this machine to be "the best dialysis machine." However, the cost of dialysis was very high because of frequent machine failure requiring technical assistance. The expenses for the company were higher than the payment from Medicare. There were studies showing that overall expenses for treatment of dialysis patients is lower with daily hemodialysis because of lower expenses for additional hospitalizations, blood pressure and anemia medications in spite of higher cost of more frequent dialysis. 190 The authors suggested to capitate the payment for all expenses in dialysis patients or provide additional payment to the dialysis provider for extra dialysis treatments. There was no question of the superiority of frequent (5-7 times weekly) hemodialysis over routine (thrice weekly) dialysis, Figure 19 One of the patients during training for home hemodialysis on the personal hemodialysis system (PHD). His wife participated in the training. This patient had a complete anuria. After 1 week on daily dialysis he said that for the first time in many years, he felt like his thinking was clearer, not hazy as before. [Color figure can be viewed at wileyonlinelibrary.com] not only on the basis of the clinical trial of PHD for FDA approval, but also on the basis of numerous other trials. Unfortunately, more frequent dialysis was more expensive, so those involved in daily (frequent) dialysis wanted increased reimbursement from Medicare. However, no higher reimbursement "would be considered" before randomized controlled study provided proof of improved outcomes with more frequent hemodialysis.
In addition to the fact that the reimbursement was inadequate for more frequent dialysis, the main problem was the slow improvement in machine reliability. A faster improvement would have dramatically lowered the cost and increased the number of centers and patients using the machine. Ultimately, the company went in dire financial straits, went bankrupt. All patients had to be taken off of PHD. The patients were very unhappy as they had to go to the less desirable system or use the regular machines for thrice weekly dialysis.
The patents of PHD were acquired by DEKA Company, which started to work on the next generation of personal hemodialysis system. In 2011, Baxter bought all patents and started to work on the machine called Vivia. This machine was similar to the PHD, but instead of the tank system it had a proportional system. The machine received approval for clinical use in 2016 in the United States and Europe, but Baxter subsequently decided to abandon the idea and stop using the machine for undisclosed reasons.
Since 2002, there was some increase in home hemodialysis in the United States, but the number of patients at home never increased over 2% of dialysis patients. There were some new machines created and accepted for clinical use. Home hemodialysis is more popular in other countries than in the United States. The highest percentage of home hemodialysis patients are in New Zealand (19% in 2012) then Australia (9%), Denmark (6%), Finland, Canada, UK, Sweden, The Netherlands, Hong Kong, Scotland, and Ireland (over 2%). In Australia and New Zealand (ANZ) all costs for home dialysis are covered by insurance, machines are the same as in centers, water treatments are installed in homes, and the doctors get allowance for home dialysis. In the United Sates, Medicare was supposed to increase fees for home and more frequent hemodialysis in 2017. 191 Unfortunately, we recently learned that only training reimbursement costs went up with an add on of $45 per training to add on of $95 per training and nothing more.
FALLACIES OF RANDOMIZED CONTROLLED TRIALS IN HEMODIALYSIS RESEARCH
Assessment of differences
The issue of statistical significance versus clinical importance was the subject of an excellent review by the late Feinstein in 1988. 192 According to him, while assessing the "significance" of difference, one has to be aware of the kind of difference under study: ranking, quantitative, stochastic, clinical (mortality and quality of life), and architectural (quality of comparison). We will not discuss ranking differences, which are used in competitions and are always significant. Another difference, which also does not require statistical analysis, is quantitative difference [an apparently large difference that fulfills the criterion of the "traumatic interocular test" (TIT)]: a difference so profound and obvious that, metaphorically, it hits one between the eyes. "You do not need a fancy P value or other statistics to say, "Yes, that's a real difference," 192 Some such landmark examples include thyroxine for myxedema in 1891, insulin for diabetic ketoacidosis in 1922, vitamin B12 for pernicious anemia in 1926, penicillin for G+ cocci sepsis in 1941, defibrillation for ventricular fibrillation in 1948 and imatinib for chronic myeloid leukemia in 2002 and gastrointestinal stomach tumors in 2005. 193 The result in the first patient on chronic hemodialysis (Clyde Shields) also belongs to this category (7) . The third type of difference is stochastic. The word stochastic, from the Greek word στoχαζεσθαι (stokhazesthai-to guess), indicates the idea of randomness, that is, how chancy the difference is. This is the ordinary meaning of the term "statistical significance." Historically, different levels of certainty were established to qualify whether the difference between the groups was real or incidental. 194 This concept was primarily studied by two major schools of thought in the 1920s and the 1930s. 195 The school of Fisher 196 propounded that if the difference between the means of two groups was small, then the groups were deemed to be from the same population with the same mean (null hypothesis). Fisher established that a P value of <0.05 (chance difference probability of <1/20) be considered significant and the null hypothesis should therefore be rejected. The second school, of Neyman and Pearson, introduced the concept of "errors." The error that incorrectly rejects the null hypothesis is called Type I or α error, whereas the error that incorrectly accepts the null hypothesis is called a Type II or β error. 197 This error is caused by insufficient sample size. Later, Kimball 198 postulated a Type III error, an error that gives the The need to shift the focus to sodium removal in dialysis patients
Hemodialysis International 2018; 22:S29-S64 S55 right answer to the wrong problem. A Type IV error was subsequently postulated as a type of error that solved the right problem too late. 199 By comparison of two groups of subjects, the higher the difference between the groups, the smaller the number of subjects needed to show a stochastic significance at the level of P < 0.05. Only 10 subjects may be needed in each group if the mortality in one group is 80% and 20% in the other group. On the other hand, a trivial difference in mortality such as between 37% and 36% between the two groups would require >9000 subjects in each group to prove that the difference of 1% is stochastically significant but still may be clinically irrelevant. "The results are splendid for policymaking decisions of pharmaceutical companies and regulatory agencies." However, they "may not be pertinent to the important distinctions of pertinent clinical subgroups that must be considered when treatment is chosen for individual patients." 194 
HOW TO DETERMINE THE STOCHASTIC DIFFERENCE?
Randomized controlled trials
Randomized Controlled Trials (RCTs) are considered the most reliable of such methods. In the early 1920s, a method for randomization of experimental studies was established by Sir Ronald Aylmer Fisher, a statistician at the Rothamsted Agricultural Experimental Station. The problem that was being studied was to compare the effects of different fertilizers on the yields of potatoes. 200 The old method was to apply each fertilizer to an entire field and compare yields between fields. Because some fields may be more fertile than others, Fisher divided the fields into rows and then into small plots within the rows, randomly assigning fertilizers to the plots before assessing the results for each fertilizer. Nowadays, RCTs are considered "a must" to establish the reliability of an observed difference. The RCT as performed by Fisher gave excellent results. However, it is open to question if the same can be said for its universal applicability in medical research, particularly when studying therapeutic methods or devices. This is due to the fact that there are inherent differences in the nature of the scientific question that was studied by Fisher and the RCTs in medicine as they apply to the study of methods. Potatoes and plots are different from patients, as nobody asks them to agree to be assigned to a particular row; there are no exclusions; they are not asked to do anything; they are always compliant; they do not withdraw from a trial, they do not switch plots; comparison is free of bias; no special equipment, venue or skills are needed for different plots. Extrapolating the need for randomization to all clinical hypothesis testing (or else the clinical equipoise would be violated) can create problems. Hill, who introduced RCTs in medicine, himself, warned that "any belief that the controlled trial is the only way would mean not that the pendulum had swung too far but that it had come right off its hook." 201 Moreover, there is an important difference between the studies of pharmaceuticals and therapeutic methods. In the study of pharmaceuticals, one group takes one medication and another group a placebo or another medication. In the study of therapeutic methods, the patients are asked to perform procedures with different pieces of equipment and/or at different venues. This creates inherent problems with recruitment and compliance of subjects with such studies.
Observational studies
Observational studies are often considered inferior to RCTs, but are they? All the quantitative differences fulfilling the criterion of TIT were achieved in historical controlled trials. In the middle of the 20th century, Doll and Hill performed case-controlled studies strongly suggesting that smoking was associated with lung cancer. 202, 203 Owing to a lack of randomization, they invoked criticism from Fisher. 204 However, there was a criticism of Fisher that "his views may also have been influenced by personal and professional conflicts, by his work as a consultant to the tobacco industry, and by the fact that he was himself a smoker." 205 Nevertheless, according to these casecontrolled studies, cigarette smoking is considered harmful with many legislating mandates based on this association although it has never been confirmed in RCTs.
Before-and-after designs
As mentioned earlier between March 1969 and May 1973, Twardowski carried out research to determine the optimal duration and frequency of dialysis that would eradicate all symptoms and signs of uremia and lead to full rehabilitation. This could then be considered adequate dialysis. Statistical evaluation by the before-andafter method using Student's paired t test showed that more frequent and/or longer HDs improved the control of blood pressure, hematocrit, serum albumin, and nerve conduction velocity. The results were so impressive that he predicted that more frequent and long dialysis would soon be the standard of care. 25 This prediction proved to be wrong, not because the conclusions were wrong, but because the development of dialysis turned in another direction.
Randomized controlled studies in dialysis
The major incentives to shorten dialysis were economical and organizational and there was a perceived need to dialyze all the patients during, at most, three hemeral shifts in the clinics. The support for this approach came from the National Cooperative Dialysis Study (NCDS). As previously described the NCDS had numerous errors and was a clear example of tremendous difficulties in using RCT in dialysis. Contrary to the observational studies leading to improved dialysis results, this randomized controlled study may have adversely impacted survival on HD in the United States. As previously mentioned, the HEMO study did not provide a correct answer. Higher dose of dialysis was achieved by higher Kt/V, but mostly by increased blood flow (higher K by 21% and higher t by 15%). Combining "K" and "t" for the measurement of dialysis dose is inappropriate. In our opinion, the HEMO study committed a Type III statistical error-asking the wrong question and achieving the correct answer: if higher Kt/V is achieved mainly by increased blood flow (K), the beneficial effect of increased (t) is thwarted by higher K.
What about the frequency of dialysis? As mentioned above, in the late 1960s and the early 1970s, there were studies, either with historical controls or based on the "before and after method" showing that more frequent HDs were superior to less frequent ones. The outcomes were all very similar and none of these reports showed worse results with more frequent dialysis. The conclusions were based on before and after designs so the mortality could not be compared. There was no question about the superiority of frequent (5-7 times weekly) HD to routine (thrice weekly) dialysis. Unfortunately, more frequent dialysis was more expensive so those involved in daily (frequent) dialysis wanted increased reimbursement from Medicare. Prior to making a decision on this issue, NIH summoned a Task Force on Daily Dialysis in Washington, DC, on April 11, 2001 . In spite of the arguments of those who personally observed excellent clinical and laboratory results of more frequent dialysis, the conference decided that observational studies are unreliable and RCTs would be needed to justify higher reimbursement. According to physicians practicing daily dialysis, the probability that numerous observational studies showing improved results with more frequent HD were wrong was close to zero (if, compared with RCTs). Originally, it was assumed that mortality would be considered a primary outcome in such a trial. The reality turned out to be different. Within a few years, it was obvious that recruitment would be a problem. In 2007, Suri et al. 206 admitted that problems with recruitment of subjects forced them to abandon comparison of mortality. The problem with recruitment of volunteers for such a study should not be surprising as it was impossible to compare results of peritoneal dialysis and HD in a RCT. 207 Anyway, the prospective randomized study comparing more frequent dialysis with conventional dialysis was started by the Frequent Hemodialysis Network group, lasted almost 10 years, cost millions of dollars and the results were published in December 2010. 208 Only 245 patients could be randomized and randomization did not include the average patient population as mortality in the control (conventional dialysis) group was only 7.5%, whereas mortality in the US population was over 18.5%. The patients already on more frequent dialysis were excluded, which created another selection bias. The patients on more frequent HD were dialyzed in centers on regular machines instead of machines suitable for more frequent HD at home. At least this RCT did not commit a Type II or III statistical error; however, it committed a Type IV error, "solving the problem too late."
The fourth RCT in HD, fraught with the usual problems faced when such trials are undertaken (inadequate enrollment) resulting in misleading results, was recently published. 209 Only 87 patients could be randomized for this study. Contrary to the study of frequent short dialysis, where patients with substantial residual renal function were excluded from randomization, 57.2% of patients in the control group had a urine output of over 500 mL/day (including 19.1% who had urine output over 1000 mL/day). Patients with a urine output of over 1000 mL/day do not require high-dose dialysis. In the past, such patients were not dialyzed, until their urine output dropped to 1000 mL/day. 25 Further indication of an inappropriate selection of patients for randomization is the fact that mortality in the conventional arm was 1/42 = 2.38%, which is at least 7 times lower than in the general population of HD patients in the United States. Many patients in the control group performed more frequent dialysis sessions and those in the more frequent group performed less frequent dialysis (so they did not behaved like plots in the Fisher's trial of potato fertilizers). The ultimate conclusion that was reached was that the frequent nocturnal dialysis study group had improvement in "control of hyperphosphatemia and hypertension but no benefit among other main secondary outcomes." All in all, this study committed a Type II statistical error because of evidently small number and inappropriate selection of subjects. On the basis of this study, it absolutely cannot be accepted that frequent nocturnal HD is not better than conventional thrice-weekly HD. However, it did not exclude that longer dialysis thrice weekly is not better than short thrice weekly dialysis.
S57
This study was not accepted for publication in the New England Journal of Medicine because of its shortcomings. Interestingly, Kidney International, where this study was ultimately published, highlights the rather misperceived notion that frequent nocturnal HD is not better all too glaringly on its cover: "No benefit from frequent nocturnal HD." In the section Polar View in Nephrology in the Nephrology Dialysis Transplantation, we published a criticism of RCTs in dialysis therapy. 210 
CONCLUSION
Hemodialysis for chronic renal failure was introduced in Seattle, WA, in 1960s. In 5 years it was determined that the best dialysis method is 3 times weekly for total of 20-40 hours. In 1964, home hemodialysis was successfully tried in one patient. In other centers in the United States and in Europe it was tried to shorten dialysis time to take more patients for treatment. Short dialysis 3 times weekly was widely accepted in the United States after prospective randomized study, national cooperative dialysis study (NCDS) postulated that adequate dialysis can be achieved, if short time is compensated by high efficiency removal of urea. After this study a Kt/V urea index was established as a measure of dialysis adequacy. Mortality, which was very low in the United States in 1970s markedly increased after shortening dialysis time. Gradually dialysis time was increasing in the United States, although it is still shorter than in Japan and many centers in Europe where dialysis time is longer and complications of dialysis are rare. More frequent than three times weekly without "Two Day Killer Gap" and longer dialysis have been tried and determined by observational studies, particularly before and after designs, that the results are markedly better. Home hemodialysis was introduced in many centers in the world; however, this method is still not popular in the United States. This article described the history of dialysis methods developments and various study methods. It is worth to stress that randomized controlled trials have been useless in the study of dialysis methods.
